Atypical depression is a specifier applied to major depressive disorder when certain features are present: mood reactivity (the patient brightens in response to positive events, which classic melancholic depression does not), increased appetite or weight gain, hypersomnia rather than insomnia, leaden paralysis in the limbs, and long-standing interpersonal rejection sensitivity. The specifier requires mood reactivity plus at least two additional features.
The clinical reality: many patients with depression do not fit the classic melancholic picture of early-morning awakening, weight loss, and pervasive anhedonia. The atypical pattern is actually quite common — particularly in younger patients, in women, in patients with bipolar spectrum disorders, and in those with onset before age 25. Recognizing it shapes treatment.
Historically, atypical depression was identified because of its preferential response to monoamine oxidase inhibitors (MAOIs) — particularly phenelzine and tranylcypromine — in trials from the 1960s-1980s. Patients with atypical features responded substantially better to MAOIs than to tricyclic antidepressants. This differential response established atypical depression as a biologically distinct phenotype, not just a different symptom cluster.
In the modern era, SSRIs and SNRIs have largely replaced MAOIs as first-line treatment — they work, and MAOIs carry dietary and drug-interaction restrictions that make them difficult to use. But for treatment-resistant atypical depression, MAOIs remain an underused tool. Many patients who have failed multiple SSRI/SNRI trials respond to MAOIs when finally offered them with appropriate tyramine counseling.
The leaden paralysis feature deserves clinical attention. Patients describe their arms and legs as made of cement — heavy, difficult to move, exhausting. This is more than fatigue; it is a specific somatic experience. The symptom is striking enough that asking about it directly can confirm the diagnosis.
Rejection sensitivity — long-standing pattern of feeling devastated by perceived interpersonal rejection — is another distinctive feature. It often predates depression onset, persists between depressive episodes, and shapes the patient's relationships. Treatment of underlying depression often improves rejection sensitivity, but the trait may persist as a vulnerability factor.
When you encounter a depressed patient who eats more, sleeps more, brightens with company, and describes a heavy leaden quality to their limbs, the atypical specifier applies. SSRIs and SNRIs first; consider MAOIs (with appropriate counseling) for refractory cases. The pattern matters because it shapes both prognosis and treatment direction.